EMvision Medical Devices Ltd
EMVision Making Strong Progress with emu and First Responder Brain Scanners
EMVision advances emu brain scanner validation; recruitment milestones hit as ischaemia endpoint eyed to bolster FDA De Novo clearance and value.
EMVision Medical Devices De-Risks Rural Stroke Use Cases with Aeromedical Study
EMVision de-risks rural stroke use with aeromedical feasibility study; First Responder Brain Scanner unaffected by flight, cash reserves of $18.4m.
EMVision Expands Pivotal FDA Trial to Include Acute Ischaemia Detection
EMVision expands FDA De Novo trial to include acute ischaemia detection for its emu device, widening indications as recruitment hits 125 and cash AUD 18.4m.
EMVision Medical Devices Activates New US Site for Pivotal emu Brain Scanner Trial
Premier US stroke research hub UCLA Health will act as the site for a validation trial and continuous innovation study of EMVision Medical Devices’ (ASX: EMV) new emu brain scanner. The trial site will be led by principal investigator Dr May Nour, a dually-trained vascular and interventional neurologist and medical director of California’s first mobile […]